Sign Up Today and Learn More About Singlera Genomics Stock
Invest in or calculate the value of your shares in Singlera Genomics or other pre-IPO companies through EquityZen's platform.
Singlera Genomics Stock (SIGE)
Singlera Genomics is a fast growing company focusing on non-invasive genetic testing.
About Singlera Genomics Stock
Founded
2014
Headquarters
La Jolla, CA, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Singlera Genomics Press Mentions
Stay in the know about the latest news on Singlera Genomics
Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
sdbn • Mar 25, 2025
Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
globenewswire • Mar 25, 2025
Methods and compositions for assessing colorectal cancer
patents • Feb 10, 2025
Multi Cancer Early Detection Research Report 2025: Global Market to Reach $2.86 Billion by 2030, Growing at a CAGR of 17% with Liquid Biopsy Segment Leading
globenewswire • Jan 15, 2025
Asia-Pacific Multi-Cancer Early Detection Market Research Report 2024: Liquid Biopsies and Advancements in Genetic Testing Gaining Momentum - Competition, Forecast & Opportunities to 2029
globenewswire • Nov 14, 2024
Singlera Genomics Management
Leadership team at Singlera Genomics
Co-Founder & Scientific advisor
KUN ZHANG
CO-Founder & CEO
JOHNY ZHANG
Join now and verify your accreditation status to gain access to:
- Singlera Genomics Current Valuation
- Singlera Genomics Stock Price
- Singlera Genomics Management
- Available deals in Singlera Genomics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Singlera Genomics Cap Table and Funding History by Share Class and Liquidity Preferences
- Singlera Genomics Revenue and Financials
- Singlera Genomics Highlights
- Singlera Genomics Business Model
- Singlera Genomics Risk Factors
- Singlera Genomics Research Report from SACRA Research
Trading Singlera Genomics Stock
How to invest in Singlera Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Singlera Genomics through EquityZen funds. These investments are made available by existing Singlera Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Singlera Genomics stock?
Shareholders can sell their Singlera Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
